Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Colorectal cancer (CRC) originates in the colon or rectum, and is the fourth leading cause of mortality among cancer patients worldwide.
The CRC pipeline is highly active and evolving. 8% of oncology’s R&D efforts are focused on CRC, and there have been 4,827 investigatory clinical trials focusing on CRC across the globe. As of May 2018, the CRC pipeline featured more than 850 products across all stages of clinical development. EGFR and VEGF inhibitors remain a key focus, particularly in regards to biosimilar development.
This report will allow you to access invaluable data on the biosimilars market.
GlobalData’s Biosimilars market report shows that CRC clinical trials have demonstrated high enrolment efficiencies. Due to the high prevalence of CRC, Phase III trials are large, and recruited an average of 680 subjects. Immunotherapy has offered diversity to the landscape with the recent launches of Keytruda and Opdivo in the US, and novel kinase inhibitors such as encorafenib + binimetinib will provide targeted therapies for currently underserved patient populations.
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.